“I was thinking about this the other night, one of the things that changed was I stopped flossing, because I figured, what’s the point?” Thomas recalls, sitting in a treatment room at START Mountain Region, reflecting on how his perspective had changed after getting his cancer diagnosis. Thomas, who works full-time as a bartender in […]
Together in the Fight Against Cancer: Thomas’ Story of Community and Care Read More »
A recent START webinar titled Malignant Hematology: Advancing Treatment in Blood Cancers, provided an in-depth look into the current advancements and challenges in treating hematological malignancies. Moderated by Dr. Andrew Sochacki, Associate Director for Hematology and Clinical Research at START Midwest, the session brought together leading experts to discuss myeloid malignancies, lymphoid malignancies, plasma cell
Antibody-drug conjugates (ADCs) are among the most promising innovations in cancer treatment today, combining the targeting precision of monoclonal antibodies with the potent killing power of cytotoxic drugs. In a recent webinar hosted by The START Center for Cancer Research (“START”), a distinguished panel of oncologists and researchers explored the science, challenges, and future directions
Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.
